[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Unidade Local de Saude do Nordeste\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100638533",false,"NCT07593638","Plasma Exchange Half-dose and Extracorporeal Detoxification for ACLF","Phoenix","Inclusion Criteria:\n\n* Written informed consent for participation in the study\n* Admission to the ICU with a diagnosis of ACLF of reversible etiology (infection, bleeding, alcohol-related, toxic, etc.)\n* Total bilirubin ≥ 12 mg\u002FdL and INR ≥ 1.5\n* On the waiting list for liver transplantation or not a candidate for transplantation but with an indication for supportive therapy\n\nExclusion Criteria:\n\n* Refusal to provide consent\n* Pregnancy\n* Expected survival \\\u003C 24 hours due to disease severity (hemodynamic instability requiring norepinephrine \\> 0.20 mcg\u002Fkg\u002Fmin and\u002For mechanical ventilation with PaO₂\u002FFiO₂ \\\u003C 150 and\u002For non-hepatic coma)\n* ACLF severity greater than CLIF-C ACLF grade 3\n* Advanced organ dysfunction: Pulmonary (GOLD stage 3 or 4) and\u002For Cardiac (NYHA functional class III or IV)\n* Advanced or metastatic oncological disease (life expectancy \\\u003C 6 months)\n* Marked frailty syndrome or secondary sarcopenia\n* Participation in another clinical trial within the previous 3 months","ALL","18 Years",{"count":18,"type":19},240,"ESTIMATED","INTERVENTIONAL",[22],"NA","Clinical trial\n\nThe goal of this clinical trial is to learn if a liver support protocol works to treat Liver failure in adults. The main questions it aims to answer are:\n\n* Does hemoadsorption plus half-dose plasma exchange provide support to liver failure patients until recovery or transplant\n* What medical problems do participants have during the technique? Researchers will compare DPMAS plus half-dose plasma exchange with conventional treatment to evaluate a gain in recovery\n\nParticipants will:\n\n* Be submitted to DPMAS plus half dose plasma exchange daily according to protocol.\n* Monitoring will be continuous in the ICU",[25],"Acute on Chronic Liver Failure (ACLF)",[27,28,29],"DPMAS","Plasma exchange","ACLF","NOT_YET_RECRUITING","2026-05-11",{"date":33,"type":34},"2026-05-18","ACTUAL",{"date":36,"type":19},"2026-07",{"date":38,"type":19},"2028-01",{"name":40,"class":41},"Unidade Local de Saude do Nordeste","OTHER",""]